AM-301 Nasal Spray Outperforms Saline in Treating Seasonal Allergic Rhinitis Symptoms

A recent clinical trial has found that AM-301, a barrier-forming nasal spray, is more effective than saline spray in managing symptoms of seasonal allergic rhinitis (SAR). The study compared the two treatments in 100 patients over two weeks, focusing on efficacy, safety, and tolerability.

Patients using AM-301 showed a significantly greater reduction in the Total Nasal Symptom Score (rTNSS), with a mean difference of -1.1 (p = 0.013), compared to those using saline. This improvement was consistent across all individual nasal symptoms.

Secondary endpoints, including the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), also favored AM-301, with significant enhancements in overall quality of life (p < 0.001) and in each RQLQ domain.

AM-301 users reported fewer instances of needing relief medication and experienced more symptom-free days compared to the saline group. Both treatments demonstrated similar safety and tolerability profiles, with no significant adverse events.

These results highlight the advantages of AM-301's barrier approach in treating SAR, offering not only improved symptom management but also enhanced quality of life, without compromising safety. This study suggests that AM-301 could be a superior alternative to saline sprays for patients seeking effective, drug-free relief from seasonal allergic rhinitis.